Philadelphia, Pennsylvania 19106

  • Vascular Graft Occlusion


The study will look at the safety profile (unwanted effects) of the long-lasting anticoagulant PEG-hirudin (SPP200) and compare these unwanted effects to those of unfractionated heparin, commonly used in haemodialysis to avoid clotting of the graft and of the haemodialysis machine.


- Patients undergoing chronic haemodialysis via an arteriovenous graft - Arteriovenous graft in place for at least 3 months - Duration of haemodialysis of at least 3 months, with 3 full dialysis sessions per week with a duration between 2 and 5 hours per session - Women patients must be either postmenopausal for more than 1 year or, if of childbearing age, must use adequate contraception - Women patients must have a negative serum pregnancy test within one week of randomisation - Able to provide written informed consent prior to study participation



Primary Contact:

Study Chair
Jessica M Mann, MD, PhD
Speedel Bio Ltd

Backup Contact:


Location Contact:

Philadelphia, Pennsylvania 19106
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: March 26, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.